HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation (RIVAL - AR EFS)

HLT

Status: Withdrawn

Conditions: Aortic Regurgitation

Treatments: Device: The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05409378

HLT2101

Details and patient eligibility

About

To evaluate the safety and performance of The Meridian® TAVR Valve in patients with severe aortic regurgitation who present at high risk for aortic valve replacement surgery.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subject has evidence of severe aortic regurgitation as assessed by the independent echo core lab according to an integrative multiparametric based on ASE (American Society of Echocardiography) guidelines considering qualitative and quantitative measures.
2. Symptoms due to severe aortic regurgitation with a NYHA Functional Classification of II or greater
3. Documented aortic valve annular diameter ≥ 21 and ≤ 26 mm (associated perimeter range is 66.0 - 81.7 mm or associated area range of 346 - 531 mm^2) measured by the MSCT Core Lab assessment of pre-procedure imaging
4. Documented heart team agreement of high risk for surgical aortic valve replacement (SAVR)
5. Geographically available, willing to comply with follow-up and able to provide written informed consent.

Exclusion criteria

1. Congenital, unicuspid or bicuspid aortic valve which could compromise procedural success

2. Severe mitral or tricuspid valve regurgitation

3. Moderate to severe mitral stenosis

4. Myocardial infarction within the past 30 days*

5. Echocardiographic evidence of intracardiac mass, thrombus or vegetation

6. Left Ventricular Ejection Fraction (LVEF) < 35%

7. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure

8. Hemodynamic instability requiring inotropic drug therapy within the past 30 days

9. Untreated clinically significant coronary artery disease requiring revascularization

10. Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure, except for PCI which is performed within 7 days prior to the index procedure*

11. Presence of significant aortic disease such as atheroma, thrombus, dissection (> 50 mm in diameter or which could be considered high risk for dissection) or aneurysm which precludes safe implant delivery

12. Blood dyscrasias defined as leukopenia (White blood cell count < 1,000 cell/mm^3), anemia (hemoglobin < 9.0 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm^3), history of bleeding diathesis or coagulopathy

13. Patient ineligible for or refuses blood transfusions

14. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity) that would preclude passage of 18F catheters from the femoral arterial access to the aorta by the MSCT Core Lab assessment of pre-procedure imaging

15. Active peptic ulcer or gastrointestinal bleeding requiring hospitalization or transfusion within the past 90 days, that would not allow treatment with the protocol antiplatelet regimen post implant *

16. Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 months, or treatment of carotid stenosis within past two months*

    • At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

The HLT® Meridian® TAVR Valve

Experimental group

Description:

Transcatheter aortic valve replacement with the HLT Meridian TAVR Valve

Treatment:

Device: The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)